Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor

Translational Oncology(2021)10.1016/j.tranon.2021.101099Source: DataRank Database

Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor is a research paper published in Translational Oncology (2021). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

gen nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)OA: goldTopics (5)IDs (PubMed, PMC)Annotations (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Andee M. Beierle,Adele P. Williams,Raoud Marayati ORCID,Laura V. Bownes ORCID,Hooper R. Markert ORCID

Live enrichment

PubMed:33887553 PMC:PMC8086143

National Cancer Institute

Grant: T32CA183926

National Cancer Institute

Grant: T32 CA229102

National Institutes of Health

Grant: CA013148

National Institutes of Health

Grant: P30 AI27667

National Institutes of Health

Grant: P30 AR048311

NCI NIH HHS

Grant: P30 CA013148

NIGMS NIH HHS

Grant: T32 GM008361

National Institutes of Health

National Cancer Institute

goldLicense: cc-by-nc-nd

publisherhttps://www.sciencedirect.com/science/article/pii/S1936523321000917/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1936523321000917?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1936523321000917?httpAccept=text/plain

repositoryhttps://doaj.org/article/ba8c4f5263934279a3ed4ec995b89d8c

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8086143

Keywords

Drug resistanceTargeted TherapyNeuroendocrine TumorCrizotinibPatient Derived Xenoline

Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor

FAIR Checklist

Authors (12)

Funding (9 grants)

Open Access

Topics

Annotations (Europe PMC)